Current Approaches for Glioma Gene Therapy and Virotherapy
- Autores
- Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; Carney, Stephen V.; Yu, Jin; Alghamri, Mahmoud S.; Asad, Antonela Sofía; Nicola Candia, Alejandro Javier; Varela, Maria Luisa; Candolfi, Marianela; Lowenstein, Pedro R.; Castro, Maria G.
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.
Fil: Banerjee, Kaushik. University of Michigan; Estados Unidos
Fil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; Argentina
Fil: Haase, Santiago. University of Michigan; Estados Unidos
Fil: McClellan, Brandon L.. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Carney, Stephen V.. University of Michigan; Estados Unidos
Fil: Yu, Jin. University of Michigan; Estados Unidos
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Varela, Maria Luisa. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria G.. University of Michigan; Estados Unidos - Materia
-
FMS-LIKE TYROSINE KINASE 3 LIGAND
GENE THERAPY
GLIOMA
HSV1-TK
IMMUNOTHERAPY
MUTANT IDH1 3
NON-VIRAL VECTORS
VIRAL VECTORS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/214289
Ver los metadatos del registro completo
id |
CONICETDig_bb22d3f053796718f76f9f2f328a5226 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/214289 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Current Approaches for Glioma Gene Therapy and VirotherapyBanerjee, KaushikNúñez Aguilera, Felipe JavierHaase, SantiagoMcClellan, Brandon L.Faisal, Syed M.Carney, Stephen V.Yu, JinAlghamri, Mahmoud S.Asad, Antonela SofíaNicola Candia, Alejandro JavierVarela, Maria LuisaCandolfi, MarianelaLowenstein, Pedro R.Castro, Maria G.FMS-LIKE TYROSINE KINASE 3 LIGANDGENE THERAPYGLIOMAHSV1-TKIMMUNOTHERAPYMUTANT IDH1 3NON-VIRAL VECTORSVIRAL VECTORShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.Fil: Banerjee, Kaushik. University of Michigan; Estados UnidosFil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; ArgentinaFil: Haase, Santiago. University of Michigan; Estados UnidosFil: McClellan, Brandon L.. University of Michigan; Estados UnidosFil: Faisal, Syed M.. University of Michigan; Estados UnidosFil: Carney, Stephen V.. University of Michigan; Estados UnidosFil: Yu, Jin. University of Michigan; Estados UnidosFil: Alghamri, Mahmoud S.. University of Michigan; Estados UnidosFil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Varela, Maria Luisa. University of Michigan; Estados UnidosFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria G.. University of Michigan; Estados UnidosFrontiers Media2021-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/214289Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-301662-5099CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnmol.2021.621831/fullinfo:eu-repo/semantics/altIdentifier/doi/10.3389/fnmol.2021.621831info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:02:50Zoai:ri.conicet.gov.ar:11336/214289instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:02:51.008CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Current Approaches for Glioma Gene Therapy and Virotherapy |
title |
Current Approaches for Glioma Gene Therapy and Virotherapy |
spellingShingle |
Current Approaches for Glioma Gene Therapy and Virotherapy Banerjee, Kaushik FMS-LIKE TYROSINE KINASE 3 LIGAND GENE THERAPY GLIOMA HSV1-TK IMMUNOTHERAPY MUTANT IDH1 3 NON-VIRAL VECTORS VIRAL VECTORS |
title_short |
Current Approaches for Glioma Gene Therapy and Virotherapy |
title_full |
Current Approaches for Glioma Gene Therapy and Virotherapy |
title_fullStr |
Current Approaches for Glioma Gene Therapy and Virotherapy |
title_full_unstemmed |
Current Approaches for Glioma Gene Therapy and Virotherapy |
title_sort |
Current Approaches for Glioma Gene Therapy and Virotherapy |
dc.creator.none.fl_str_mv |
Banerjee, Kaushik Núñez Aguilera, Felipe Javier Haase, Santiago McClellan, Brandon L. Faisal, Syed M. Carney, Stephen V. Yu, Jin Alghamri, Mahmoud S. Asad, Antonela Sofía Nicola Candia, Alejandro Javier Varela, Maria Luisa Candolfi, Marianela Lowenstein, Pedro R. Castro, Maria G. |
author |
Banerjee, Kaushik |
author_facet |
Banerjee, Kaushik Núñez Aguilera, Felipe Javier Haase, Santiago McClellan, Brandon L. Faisal, Syed M. Carney, Stephen V. Yu, Jin Alghamri, Mahmoud S. Asad, Antonela Sofía Nicola Candia, Alejandro Javier Varela, Maria Luisa Candolfi, Marianela Lowenstein, Pedro R. Castro, Maria G. |
author_role |
author |
author2 |
Núñez Aguilera, Felipe Javier Haase, Santiago McClellan, Brandon L. Faisal, Syed M. Carney, Stephen V. Yu, Jin Alghamri, Mahmoud S. Asad, Antonela Sofía Nicola Candia, Alejandro Javier Varela, Maria Luisa Candolfi, Marianela Lowenstein, Pedro R. Castro, Maria G. |
author2_role |
author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
FMS-LIKE TYROSINE KINASE 3 LIGAND GENE THERAPY GLIOMA HSV1-TK IMMUNOTHERAPY MUTANT IDH1 3 NON-VIRAL VECTORS VIRAL VECTORS |
topic |
FMS-LIKE TYROSINE KINASE 3 LIGAND GENE THERAPY GLIOMA HSV1-TK IMMUNOTHERAPY MUTANT IDH1 3 NON-VIRAL VECTORS VIRAL VECTORS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM. Fil: Banerjee, Kaushik. University of Michigan; Estados Unidos Fil: Núñez Aguilera, Felipe Javier. Fundación Instituto Leloir; Argentina Fil: Haase, Santiago. University of Michigan; Estados Unidos Fil: McClellan, Brandon L.. University of Michigan; Estados Unidos Fil: Faisal, Syed M.. University of Michigan; Estados Unidos Fil: Carney, Stephen V.. University of Michigan; Estados Unidos Fil: Yu, Jin. University of Michigan; Estados Unidos Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina Fil: Varela, Maria Luisa. University of Michigan; Estados Unidos Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos Fil: Castro, Maria G.. University of Michigan; Estados Unidos |
description |
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/214289 Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-30 1662-5099 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/214289 |
identifier_str_mv |
Banerjee, Kaushik; Núñez Aguilera, Felipe Javier; Haase, Santiago; McClellan, Brandon L.; Faisal, Syed M.; et al.; Current Approaches for Glioma Gene Therapy and Virotherapy; Frontiers Media; Frontiers in Molecular Neuroscience; 14; 3-2021; 1-30 1662-5099 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnmol.2021.621831/full info:eu-repo/semantics/altIdentifier/doi/10.3389/fnmol.2021.621831 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613837240664064 |
score |
13.070432 |